CDSL Share Price & More: Trading Strategies for June 2 (Manappuram, Wockhardt, HDFC Life, GSK Pharma)
The stock market is full of surprises. On June 2, 2025, one of the biggest movers was CDSL, with its share price jumping sharply. This caught the eye of many traders. But CDSL wasn’t alone. Other stocks like Manappuram, Wockhardt, HDFC Life, and GSK Pharma also made interesting moves.
We know that staying updated with market trends helps us make smart trading choices. So today, we’ll look at how these five stocks performed. We’ll also talk about simple trading ideas that might help us this week.
Let’s break down each stock, study the trends, and see what actions we can take now.
CDSL: A Bullish Breakout
CDSL stock jumped about 10% on June 2 and touched ₹1,680. This marks a 60.4% increase from its March low of ₹1,047.5.
The stock is moving above its 20, 50, 100, and 200-day simple average lines. This indicates strong bullish momentum.
Currently, CDSL has a Price-to-Earnings (P/E) ratio of 52x for FY26E and 42x for FY27E. HDFC Securities has given an “ADD” rating and set a target of ₹1,180, based on 38 times the expected earnings for FY27.
Trading Strategy:
- Short-term traders might consider booking partial profits due to high valuations.
- Long-term investors could hold and anticipate continued growth in the financial market infrastructure.
Manappuram Finance
On June 2, 2025, Manappuram Finance stock finished the day at ₹238.00. The stock has been trading within a stable range. It shows resilience amid market fluctuations.
Trading Strategy:
- Investors might adopt a wait-and-watch approach and monitor for a breakout above ₹247.60 for potential upside.
Wockhardt
Wockhardt shares edged up 0.05% on June 2. However, the company’s latest P/E ratio stands at -417.51x, reflecting ongoing financial challenges.
Trading Strategy:
- Investors need to be careful because the company has reported losses.
- Potential investors might await clearer signs of financial turnaround before entering positions.
HDFC Life: Stability in Uncertain Times
HDFC Life shares traded at ₹765.00 on June 2, down 1.53% amid market uncertainty. The stock is seen as a stable option. Its six-month beta is 0.8781. It shows low risk as compared to the overall market risk.
Trading Strategy:
- Investors seeking stability might consider holding.
- Those concerned about high valuations may look for better entry points.
GSK Pharma: A Global Player’s Steady Course
GSK Pharma shares closed at 1,515.50p on June 2, up 0.56%. The stock is trading 8.9% lower than its highest price of 44.67 in the past 52 weeks. This suggests growth potential.
Trading Strategy:
Long-term investors may start buying small amounts. They can wait for the stock to grow over time. The price might rise back to its old high level.
Final Words
On June 2, 2025, the CDSL share price shows strong bullish momentum, but high valuations warrant caution. Manappuram is holding a steady price. If it moves above a strong level, there could be a chance for the price to rise. Wockhardt faces challenges, and suggests a cautious approach. HDFC Life offers stability, though high valuations may deter some investors. GSK Pharma presents a steady investment with room for growth.
Investors should align their strategies with individual risk appetites and market outlooks. They should consider both technical indicators and fundamental analyses.
Frequently Asked Questions (FAQs)
HDFC Life share price may rise if the company earns more profit, gains new customers, or market conditions improve. But the price can also drop, so there is no sure result.
HDFC Life has about 2.15 billion shares in total. This number shows how many parts the company is divided into for public trading on the stock market.
Disclaimer:
This content is for general information only; do not take it as financial advice. Always do your research before making any financial decisions.